Living methods for living guidelines: Changes to evidence synthesis methods in the Australian National Clinical Evidence Taskforce COVID‐19 living guidelines

Author:

White Heath1ORCID,Turner Tari1,Beecher Claire1,Poole Alex1,McDonald Steve1ORCID,Hewitt Jessie1,Chakraborty Samantha1,Fraile‐Navarro David1,Cheyne Saskia1,Vogel Joshua2,Jeppesen Britta Tendal3,McGloughlin Steve4,

Affiliation:

1. School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia

2. Burnet Institute Melbourne Victoria Australia

3. Future Evidence Foundation Melbourne Victoria Australia

4. Alfred Health Melbourne Victoria Australia

Abstract

AbstractLiving evidence methods, such as those used to produce living guidelines, can evolve over time as the context or evidence changes. In Australia, the National Clinical Evidence Taskforce has been developing living guidelines for the management and care of people with coronavirus disease 2019 (COVID‐19) since March 2020, undertaking daily searches, and producing over 130 updates of more than 200 recommendations. Over the 3 years of the guidelines, the methods have also been ‘living’. In this paper, we describe why, how and with what impact changes to our methods have been made. When changes were required to the methods, the Taskforce Evidence Team developed a ‘Methods Brief’ outlining the proposed changes, rationale and any risks. This was presented to the Guidelines Leadership Group for approval and to the Steering Committee for noting. Changes were then reflected in the online, publicly available description of our methods. Methods to develop the living guidelines evolved through five phases, reflecting changes in the availability of evidence, the degree and nature of clinical uncertainty and resource availability. Largely these changes were to the criteria we used to select evidence for inclusion, and our expected level of responsiveness to new evidence. In the initial phases, inclusion criteria were very broad, and as the evidence base stabilised our focus narrowed to areas of high clinical importance and evidence certainty. The rapidly evolving nature of the pandemic, understanding of the illness, clinical questions and evidence base during development of the living COVID‐19 guidelines, necessitated multiple changes to the methods used to produce the guidelines. In this context, the ongoing revision of the methods for living guideline production was a necessity and a strength of the living approach. Questions remain about how best to ensure rigour is maintained while methods evolve.

Funder

Department of Health, State Government of Victoria

Ian Potter Foundation

Equity Trustees

Publisher

Wiley

Reference10 articles.

1. National Institute for Health and Clinical Excellence (NICE). NICE Strategy 2021 to 2026 [Internet]. 2021 [updated 2021 April; cited 2023 Nov 12]. Available from:https://www.nice.org.uk/about/who-we-are/corporate-publications/the-nice-strategy-2021-to-2026

2. World Health Organization (WHO). Living Guidance for Clinical Management of COVID‐19. 2021 [updated 2021 Nov 23

3. cited 2023 Nov 12]. Available from:https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2

4. Weekly updates of national living evidence-based guidelines: methods for the Australian living guidelines for care of people with COVID-19

5. Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3